"Azacitidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Descriptor ID |
D001374
|
MeSH Number(s) |
D02.145.150 D03.383.742.680.245.217 D13.570.685.245.217 D13.570.800.286.300
|
Concept/Terms |
Azacitidine- Azacitidine
- 5-Azacytidine
- 5 Azacytidine
- Azacytidine
|
Below are MeSH descriptors whose meaning is more general than "Azacitidine".
Below are MeSH descriptors whose meaning is more specific than "Azacitidine".
This graph shows the total number of publications written about "Azacitidine" by people in this website by year, and whether "Azacitidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 1 | 0 | 1 |
1997 | 3 | 1 | 4 |
1999 | 2 | 0 | 2 |
2000 | 0 | 1 | 1 |
2001 | 4 | 0 | 4 |
2002 | 3 | 0 | 3 |
2003 | 8 | 2 | 10 |
2004 | 7 | 1 | 8 |
2005 | 10 | 7 | 17 |
2006 | 9 | 4 | 13 |
2007 | 12 | 5 | 17 |
2008 | 9 | 7 | 16 |
2009 | 9 | 8 | 17 |
2010 | 14 | 4 | 18 |
2011 | 9 | 6 | 15 |
2012 | 9 | 5 | 14 |
2013 | 10 | 8 | 18 |
2014 | 6 | 8 | 14 |
2015 | 12 | 8 | 20 |
2016 | 6 | 7 | 13 |
2017 | 6 | 10 | 16 |
2018 | 5 | 10 | 15 |
2019 | 6 | 1 | 7 |
2020 | 4 | 3 | 7 |
2021 | 10 | 10 | 20 |
2022 | 9 | 11 | 20 |
2023 | 5 | 11 | 16 |
2024 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azacitidine" by people in Profiles.
-
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298.
-
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. J Immunother Cancer. 2024 Feb 28; 12(2).
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 Apr; 99(4):615-624.
-
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nat Commun. 2024 Feb 01; 15(1):972.
-
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):260-268.e2.
-
Toward an improved understanding of hypomethylating agent and venetoclax therapies. Am J Hematol. 2024 Feb; 99(2):152-154.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 Feb; 99(2):E32-E36.
-
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672.